Optomed Oyj (OPTOMED.HE)
EUR 3.95
(3.27%)
EUR 3.95
(3.27%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.97 Million EUR | -4.08% |
| 2022 | -4.07 Million EUR | -29.5% |
| 2021 | -2.9 Million EUR | -30.01% |
| 2020 | -281 Thousand EUR | -134.38% |
| 2019 | -1.17 Million EUR | -123.1% |
| 2018 | 376 Thousand EUR | 183.15% |
| 2017 | -1.65 Million EUR | 13.39% |
| 2016 | -1.9 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -649 Thousand EUR | 37.57% |
| 2024 Q2 | -1.19 Million EUR | -137.3% |
| 2023 Q2 | -424 Thousand EUR | 4.72% |
| 2023 FY | - EUR | -4.08% |
| 2023 Q4 | -702 Thousand EUR | -361.94% |
| 2023 Q3 | 268 Thousand EUR | 163.21% |
| 2023 Q1 | -445 Thousand EUR | -30.5% |
| 2022 Q3 | 290 Thousand EUR | 156.86% |
| 2022 Q4 | -341 Thousand EUR | -217.59% |
| 2022 Q2 | -510 Thousand EUR | 37.04% |
| 2022 Q1 | -810 Thousand EUR | 35.92% |
| 2022 FY | - EUR | -29.5% |
| 2021 FY | - EUR | -30.01% |
| 2021 Q1 | -76 Thousand EUR | -155.88% |
| 2021 Q2 | 280 Thousand EUR | 468.42% |
| 2021 Q4 | -1.26 Million EUR | -407.63% |
| 2021 Q3 | -249 Thousand EUR | -188.93% |
| 2020 Q4 | 136 Thousand EUR | -37.61% |
| 2020 Q2 | -246 Thousand EUR | 50.9% |
| 2020 Q3 | 218 Thousand EUR | 188.62% |
| 2020 FY | - EUR | -134.38% |
| 2020 Q1 | -501 Thousand EUR | -185.06% |
| 2019 Q3 | -546 Thousand EUR | -142.67% |
| 2019 FY | - EUR | -123.1% |
| 2019 Q4 | 589 Thousand EUR | 207.88% |
| 2019 Q1 | 30 Thousand EUR | -96.95% |
| 2019 Q2 | -225 Thousand EUR | -850.0% |
| 2018 Q3 | 155 Thousand EUR | 0.0% |
| 2018 Q4 | 984 Thousand EUR | 534.84% |
| 2018 FY | - EUR | 183.15% |
| 2017 FY | - EUR | 13.39% |
| 2016 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|